Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
18 April 2024
m 04:35 | Non-degenerate nucleotides per response element diffhist +263 Marshallsumter talk contribs (→Tabulation of counts) |
17 April 2024
|
N 20:47 | SCAPULOPERONEAL SPINAL MUSCULAR ATROPHY 3 changes history +364 [Hafiza Amna Qadeer (3×)] | |||
|
20:47 (cur | prev) −13 Hafiza Amna Qadeer talk contribs (minor edit) Tag: Visual edit | ||||
|
20:46 (cur | prev) +377 Hafiza Amna Qadeer talk contribs (new page minor edit) Tag: Visual edit | ||||
N |
|
19:33 (cur | prev) 0 Hafiza Amna Qadeer talk contribs (Created blank page) |
|
m 18:11 | Non-degenerate nucleotides per response element 2 changes history +601 [Marshallsumter (2×)] | |||
m |
|
18:11 (cur | prev) +438 Marshallsumter talk contribs (→Tabulation of counts) | |||
m |
|
06:52 (cur | prev) +163 Marshallsumter talk contribs (→Tabulation of counts) |
N 08:08 | Elranatamab-bcmm diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") |
N 08:08 | Palovarotene diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") |
N 08:08 | Pozelimab-bbfg diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") |
N 08:07 | Motixafortide diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") |
N 08:07 | Momelotinib diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") |
N 08:06 | Cipaglucosidase alfa-atga diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") |
N 08:05 | Etrasimod diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") |
N 08:05 | Zilucoplan diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") |
N 08:04 | Bimekizumab diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") |
N 08:04 | Vamorolone diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") |
N 08:04 | Mirikizumab-mrkz diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") |
N 08:03 | Toripalimab-tpzi diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") |
|
08:02 | User:Edzelco 5 changes history +99 [Edzelco (5×)] | |||
|
08:02 (cur | prev) +18 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
07:53 (cur | prev) +26 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
07:44 (cur | prev) 0 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
07:44 (cur | prev) +36 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
07:43 (cur | prev) +19 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) |
N 08:02 | Fruquintinib diffhist +25,648 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=fruquintinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy |fdaLIADAdult=Recommended Dosage The recommended dose of F...") |
|
N 07:53 | Taurolidine, heparin 2 changes history +9,993 [Edzelco (2×)] | |||
|
07:53 (cur | prev) 0 Edzelco talk contribs | ||||
N |
|
07:52 (cur | prev) +9,993 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{Edzelco}} |genericName=taurolidine, heparin |aOrAn=a |drugClass=combination of taurolidine, a thiadiazinane antimicrobial, and heparin, an anti-coagulant |indicationType=prevention |indication=atheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients...") |
N 07:43 | Repotrectinib diffhist +32,783 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=repotrectinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) |contraindications=None |warnings=5.1 Central Nervous System Adverse Reactions AUGTYRO can cause central nervous system adverse reactions. Among the 351 patients who received AUGTYRO in Study TRIDENT-1, a broad spectru...") |
|
N 07:34 | Efbemalenograstim alfa-vuxw 3 changes history +20,126 [Edzelco (3×)] | |||
|
07:34 (cur | prev) 0 Edzelco talk contribs | ||||
|
07:33 (cur | prev) +51 Edzelco talk contribs | ||||
N |
|
07:32 (cur | prev) +20,075 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |genericName=efbemalenograstim alfa-vuxw |aOrAn=a |drugClass=leukocyte growth factor |indicationType=prevention |indication=incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia |fdaLIADAdult=Recommended Dose: 20 mg administered subcutaneously once per chemotherapy cycle....") |
04:20 | Endocarditis overview diffhist +9,001 Kosar Doraghi talk contribs |
16 April 2024
|
m 17:29 | Non-degenerate nucleotides per response element 2 changes history +606 [Marshallsumter (2×)] | |||
m |
|
17:29 (cur | prev) +201 Marshallsumter talk contribs (→Tabulation of counts) | |||
m |
|
08:14 (cur | prev) +405 Marshallsumter talk contribs (→Tabulation of counts) |
|
15:06 | Trismus 3 changes history +1,038 [M. Arsalan Bashir (3×)] | |||
|
15:06 (cur | prev) 0 M. Arsalan Bashir talk contribs (→Treatment) | ||||
|
15:00 (cur | prev) +223 M. Arsalan Bashir talk contribs | ||||
|
13:30 (cur | prev) +815 M. Arsalan Bashir talk contribs (→Treatment) |
|
05:50 | User:Edzelco 2 changes history +33 [Edzelco (2×)] | |||
|
05:50 (cur | prev) +18 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
05:28 (cur | prev) +15 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) |
N 05:50 | Capivasertib diffhist +34,175 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Capivasertib |aOrAn=a |drugClass=kinase inhibitor in combination with fulvestrant |indicationType=treatment |indication=adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based...") |
N 05:27 | Iptacopan diffhist +33,311 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=iptacopan |aOrAn=a |drugClass=complement factor B inhibitor |indicationType=treatment |indication=paroxysmal nocturnal hemoglobinuria |blackBoxWarningTitle=WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA |blackBoxWarningBody=<span style="clear;"> FABHALTA increases the risk of serious and life-threatening infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria me...") |
01:37 | Birch triterpenes diffhist +1,569 Rafael Garcia talk contribs |
15 April 2024
|
21:57 | Intraosseous ganglion 9 changes history +776 [Dj (9×)] | |||
|
21:57 (cur | prev) −7 Dj talk contribs | ||||
|
21:54 (cur | prev) +116 Dj talk contribs (→Natural History of Disease) | ||||
|
21:52 (cur | prev) +31 Dj talk contribs (→Epidemiology) | ||||
|
21:51 (cur | prev) +243 Dj talk contribs (→Diagnosis) | ||||
|
21:50 (cur | prev) +236 Dj talk contribs (→Epidemiology) | ||||
|
21:48 (cur | prev) +1 Dj talk contribs (→Complications) | ||||
|
21:48 (cur | prev) +174 Dj talk contribs (→Epidemiology) | ||||
|
21:46 (cur | prev) −18 Dj talk contribs (→Complications) | ||||
|
21:45 (cur | prev) 0 Dj talk contribs (→Complications) |